Comparison between in vitro properties of washed platelet concentrates suspended in M-sol and those in BRS-A, both of which were prepared with an automated cell processor

Iwama, Akira; Hirayama, Junichi; Nogawa, Masayuki; Shiba, Masayuki; Satake, Masahiro; Takamoto, Shigeru; Tadokoro, Kenji

doi:10.1016/j.transci.2017.01.007

Cited by 10 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To effectively prevent ATRs with PC transfusion, it is important to sufficiently remove PCs during the preparation of washed PCs . In our manual method of RPC adjustment, it is possible to remove approximately 90%‐95% of plasma proteins in the preparation process, but it is difficult to remove as many plasma proteins (approximately 99%) as obtained from reported automated equipment methods . However, together with evidence from other reports targeting the same disease population of pediatric patients, our manual method of RPC preparation can effectively prevent ATRs, regardless of the type of PAS (M‐sol or BRS‐A).…”

Section: Discussionmentioning

confidence: 93%

“…Conversely, BRS‐A has the advantage of being easily adjusted by mixing two bicarbonated Ringer solutions with ACD‐A solution . A comparison of washed PC using M‐sol and BRS‐A in vitro has confirmed that the maintenance effect of platelet quality can be achieved at the same level . Washed PCs, using the classical PAS (G‐sol) have been used in Japan for many years, and the manual washing method was considered as a complicated method .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of administration of platelet concentrates suspended in M‐sol or BRS‐A for pediatric patients

et al. 2018

View full text Add to dashboard Cite

BACKGROUND Two different platelet additive solutions (PASs), M‐sol and BRS‐A, used in succession, have been reported as novel PASs in Japan. However, there are not enough clinical data comparing platelet concentrates (PCs) suspended in these PASs. STUDY DESIGN AND METHODS A retrospective cohort study of consecutive cases was performed between 2013 and 2018. For the first 30 months, children with primary hematologic and/or malignant diseases were transfused resuspended PCs in M‐sol (RPC‐M) as plasma‐replaced PCs. For the subsequent 30 months, children were transfused plasma‐replaced PCs in BRS‐A (RPC‐B) under the same conditions. Children transfused with conventional PCs (containing residual plasma) were defined as controls. We evaluated the frequency of adverse events, corrected count increment (CCI), and bleeding occurrence in the children. RESULTS Overall, 84 patients received 679 conventional PC transfusions. Allergic transfusion reactions (ATRs) occurred in 12 (14.3%) patients transfused with 12 (1.8%) bags. Fifty‐nine patients received a total of 1182 bags of RPC‐M, and one patient (1.7%) had five (0.4%) ATR episodes. During the last 30 months, 58 patients were transfused 1044 bags of RPC‐B, with ATRs occurring in four (6.9%) patients transfused with four (0.4%) bags. No other adverse events were observed with either RPC‐M or RPC‐B. CCIs (24 hr) were not significantly different for the three different PCs, and posttransfusion bleeding was not observed. CONCLUSIONS Plasma‐replaced PC using two different PAS in children appeared to prevent ATRs accompanied without other adverse events in children. Transfusion efficacy was not significant; therefore, either of the PASs could be used with equivalent results based on the clinical situation.

show abstract

Section: Discussionmentioning

confidence: 93%

mentioning

confidence: 99%

Comparison of administration of platelet concentrates suspended in M‐sol or BRS‐A for pediatric patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The residual plasma level of this product, which is prepared using an automated cell processor (ACP215, Haemonetics Corp.) is approximately 1%, and PLT properties can be preserved in vitro for at least 7 days. 1,2 Recently, a retrospective multicenter study reported that this product was effective and safe for prevention of recurrent or severe transfusion reactions. 3 PLT products are generally stored with continuous agitation to maintain their quality; however, the interruption of agitation for 24 hours has only a slight impact on the in vitro properties of washed PLTs.…”

Section: -Hour Interruption Of Agitation: Effect On Quality Of Washmentioning

confidence: 99%

“…PCs (3.0 × 10 11 PLTs) were washed on Day 1 after blood collection using the automated closed-system cell processor as described previously (N = 6). 1,2 Washed PLTs, which were rested 1 hour after preparing, were divided equally into control (120 AE 11 mL) and test units (123 AE 12 mL) using polyolefin containers (KBP600FPN, Kawasumi Co., Ltd.) on Day 1. Control units were agitated from Days 1 to 7.…”

Section: -Hour Interruption Of Agitation: Effect On Quality Of Washmentioning

confidence: 99%

“…Both units were stored at 20 to 24 C. in vitro properties were measured as previously described. 2 Statistical analyses of were performed by a 2-way repeated-measures analysis of variance with the Bonferroni post hoc test (Prism 7, Version 7.02, GraphPad Software, Inc.). A p value of less than 0.05 was considered to be significant.…”

Section: -Hour Interruption Of Agitation: Effect On Quality Of Washmentioning

confidence: 99%

See 1 more Smart Citation

48‐hour interruption of agitation: effect on quality of washed PLT suspended in BRS‐A

et al. 2019

Self Cite

View full text Add to dashboard Cite

Microfluidic technologies: buffer exchange in bioprocessing, a mini review

Carvell,

Burgoyne,

Fraser

et al. 2024

Microfluid Nanofluid

View full text Add to dashboard Cite

Buffer exchange is a common process in manufacturing protocols for a wide range of bioprocessing applications, with a variety of technologies available to manipulate biological materials for culture medium exchange, cell washing and buffer removal. Microfluidics is an emerging field for buffer exchange and has shown promising results with both prototype research and commercialised devices which are inexpensive, highly customisable and often have the capacity for scalability to substantially increase throughput. Microfluidic devices are capable of processing biological materials and exchanging solutions without the need for conventional processing techniques like centrifugation, which are time-consuming, unsuitable for large volumes and may be damaging to cells. The use of microfluidic separation devices for cell therapy manufacturing has been under-explored despite some device designs successfully being used for diagnostic enrichment of rare circulating tumour cells from peripheral blood. This mini-review aims to review the current state of microfluidic devices for buffer exchange, provide an insight into the advantages microfluidics offers for buffer exchange and identify future developments key to exploiting the technology for this application.

show abstract

Comparison between in vitro properties of washed platelet concentrates suspended in M-sol and those in BRS-A, both of which were prepared with an automated cell processor

Cited by 10 publications

References 18 publications

Comparison of administration of platelet concentrates suspended in M‐sol or BRS‐A for pediatric patients

Comparison of administration of platelet concentrates suspended in M‐sol or BRS‐A for pediatric patients

48‐hour interruption of agitation: effect on quality of washed PLT suspended in BRS‐A

Microfluidic technologies: buffer exchange in bioprocessing, a mini review

Contact Info

Product

Resources

About